SynthesisClinical drug investigation2026

Characterization of the Safety Profile of the Triple Monoamine Reuptake Inhibitor Dasotraline Based on Clinical Trial Data and Disproportionality Analyses of Four Related Pharmacological Classes Using Real-World Data from the FDA Adverse Event Reporting System.

Solomiya Gumenyuk et al.PubMed ↗Publisher ↗

No numbers read from the abstract.